

Volatility: High



R. Robert Goldman

Senior Research Analyst 443-394-3499, rgoldman@pjc.com

Daniel Meron

Research Analyst 011-972-3-753-2033, danielm@nzco.com

Reason for Report:

Change in rating, target, estimates

	From	То
Changes	(Previous)	(Current)
Rating	Outperform	Mkt Perform
Price Tgt	\$28	\$12
FY02E EPS	\$1.40	\$1.12
FY03E EPS	\$1.46	\$0.93
FY02E Rev (mil)	\$1,726	\$1,608
FY03E Rev (mil)	\$1,801	\$1,458

Price: \$14.56 52-Wk Range: \$58.00-\$14.45 Price Target: (15x forward 12-month EPS of \$0.82) 225.5 Shares Out (mil): Market Cap (mil): \$3,284 Avg Daily Vol (000): 2,928 Book Value/Share: \$6.77 Cash Per Share: \$4.62 Debt to Total Capital: 22% Div (ann) - Yield: N/A Est LT EPS Growth 20% P/E to LT Growth (2002): 0.65xEst Next Rep Date: July 2002 FY End: Sep 2002

Rev (mil)	2001	2002E	2003E
Dec	\$342.2	\$422.6A	\$358.9
Mar	\$372.3	\$455.3A	\$359.3
Jun	\$404.0	\$380.0	\$365.5
Sep	<u>\$415.4</u>	\$350.0	\$374.3
FY	\$1,533.9	\$1,607.9	\$1,458.0
CY	\$1,614.4	\$1,544.2	\$1,493.7
EV DM	0.4	0.0	0.0
FY RM	2.1x	2.0x	2.3x
CY RM	2.0x	2.1x	2.2x
EDC	0004	00005	00005
EPS	2001	2002E	2003E
Dec	\$0.27	\$0.36A	\$0.21
Mar	\$0.30	\$0.37A	\$0.22
Jun	\$0.33	\$0.20	\$0.23
Sep	<u>\$0.35</u>	<u>\$0.19</u>	<u>\$0.26</u>
FY	\$1.24	\$1.12	\$0.93
CY	\$1.34	\$0.97	\$1.00
FY P/E	11.7x	13.0x	15.7x
CY P/E	10.9x	15.0x	14.6x

Note: EPS excl goodwill and one-time items.

<u>Disclosures</u> (see last page for details):

- (#) Market Maker
- (^) Beneficial Interest
- (>) Beneficial Interest/Pre-IPO
- (@) Underwriter
- (~) Employee/Director

Amdocs Ltd. (DOX – \$14.56) Market Perform

Lowering Rating To Market Perform Following Earnings Preannouncement

KEY POINTS:

- Yesterday, after the close, DOX sharply lowered guidance for the balance of its fiscal year ending September, citing lower-than-expected new wins (in size and especially in number), due to delays in procurement decisions by the world's telecom carriers. This reflects the second reduction in guidance for 2H02 in 60 days.
- New guidance of \$380 million in Q3 sales and EPS of \$0.20 represents a 10% decrease to the previous top-line guidance and compares with expectations of \$0.33. Revised Q4 revenue expectations were taken even lower to \$350-\$360 million, down from \$428.0 million. EPS is expected to be in range of \$0.17-\$0.20.
- Management plans to reduce headcount by 10% in the next two fiscal quarters, which should help stabilize operating margin in the upper-teen range. It is unclear as to the level of restructuring costs related to these cost-reduction measures.
- In our opinion, a negative fundamental shift in the CC&B space is having a negative impact on DOX's competitive positioning and business model, which could lead to slower long-term sales growth rates of around 10%-15%
- We are lowering our rating, estimates, and price target, following this preannouncement, and believe that other shares, such as TTI Telecom (TTIL-\$21.90-SB-#@) could decline as part of the collateral damage from this news. Our new price target of \$12 reflects 15x our revised forward 12-month EPS of \$0.82 and is based upon a lower multiple than our previous target, due to the expected decline in business.

INVESTMENT RECOMMENDATION:

It appears that the negative banter in the Israeli press regarding DOX was right on the mark. Following the Billing World conference, we were able to receive confirmation that DOX had indeed not won an AT&T Wireless (#) tender worth an estimated \$100 million, and that DOX may soon be displaced at a few existing wireless customers in the coming months. Displacement would be a first, but not likely the last. Contrary to our original thesis, DOX's relatively high-cost business model just isn't well suited for the tight-fisted telecom environment. As a result, DOX's shares could continue to be under pressure for a few quarters, both competitively and from the delays cited by management.

COMPANY DESCRIPTION:

Amdocs Ltd. (#) is the largest provider of CC&B (Customer Care and Billing) information system solutions to major communications companies (90% of FY01 rev.) and directory-publishing systems worldwide. The Company employs well more than 9,000 people, with offices located strategically around the globe.

Amdocs Ltd. Page 1 of 3



Disper Jaffray

Rob Goldman, 443-394-3499, rgoldman@pjc.com Daniel Meron, 011-972-3-753-2033, danielm@nzco.com

Amdocs Ltd.
(NYSE: DOX)
Historical and Projected Income Statement
(\$ in thousands, except per share)

				Dec 01		Mar 02		Jun 02		Sep 02				
		FY01	_	1Q02A		2Q02A		3Q02		4Q02		FY02E		FY03E
License Revenue	\$	171,430	\$	42,290		45,528	\$		\$	34,600	\$	159,618	\$	148,60
Service Revenue	ľ	1,362,480	<u> </u>	380,351	Ψ	409,741	Ψ	342,800	Ψ	315,400	ľ	1,448,292	*	1,309,40
Total Revenues	\$	1,533,910	\$	422,641	\$	455,269	\$	380,000	\$	350,000	\$	1,607,910	\$	1,458,00
License		5,651		980		1,433		1,150		1,060		4,623		4,49
Maint and Service	1_	847,590		230,603		249,204	_	233,100		207,500	1_	920,407	1_	831,20
Total Cost of Revenues	\$	853,241	\$	231,583	\$	250,637	\$	234,250	\$	208,560	\$	925,030	\$	835,69
Gross Profit	\$	680,669	\$	191,058	\$	204,632	\$	145,750	\$	141,440	\$	682,880	\$	622,31
Research and Development		105,807		28,557		30,902		32,000		31,000		122,459		126,60
Selling, General, & Admin.		195,593		53,779		61,023		53,000		52,000		219,802		213,80
Amortization of Goodwill In-proc. R&D charge		219,998		56,782 30,711		61,894		62,000		62,000		242,676 30,711		248,00
, ,	\$	201 400	\$	82,336	\$	91,925	\$	85,000	\$	83,000	1-	_	\$	340,40
Total Operating Expenses	9	301,400 379,269	э \$								\$	342,261 340,619	9	281,91
Operating Income	4		Φ	108,722	\$	112,707	\$	60,750	\$	58,440	1		1	
Interest and Other Income		22,286	_	3,327	_	2,383	_	2,000	•	2,000		9,710		10,30
Pretax Income	\$	401,555	\$	112,049	\$	115,090	\$	62,750	\$	60,440	\$	350,329	\$	292,21
Income Taxes	1	120,466		31,374		32,225	_	17,600		16,900	1_	98,099	1_	81,80
Extarordinary Gain (Loss)				(76,341)			_				1_	(76,341 <u>)</u>	1_	
Net Income (Loss)	\$	281,089	\$	80,675	\$	82,865	\$	45,150	\$	43,540	\$	252,230	\$	210,41
W. I. A. B. B. B.		000 000		205 200		005 400				200 700		005 000		007.00
Wtd. Avg., Dil Shares		226,832		225,090		225,488		226,000		226,700		225,820		227,30
EPS (excl goodwill and one-times)	\$	1.24	\$	0.36	\$	0.37	\$	0.20	\$	0.19	\$	1.12	<u>\$</u>	0.9
License Revenue Service Revenue Gross:		11.2% 88.8%		10.0% 90.0%		10.0% 90.0%		9.8% 90.2%		9.9% 90.1%		9.9% 90.1%		10.2 89.8
License Gross Margin		96.7%		97.7%		96.9%		96.9%		96.9%		97.1%		97.0
Maint and Serv. Gross Margins		<u>37.8</u> %		<u>39.4</u> %		<u>39.2</u> %		<u>32.0</u> %		<u>34.2</u> %		<u>36.4</u> %		36.5
Total Gross Margin		44.4%		45.2%		44.9%		38.4%		40.4%		42.5%		42.7
Operating (as a % of Total Revs):														
Research and Development		6.9%		6.8%		6.8%		8.4%		8.9%		7.6%		8.7
Selling, General and Admin.		<u>12.8</u> %		<u>12.7</u> %		<u>13.4</u> %		<u>13.9</u> %		<u>14.9</u> %		<u>13.7</u> %		14.7
Total Operating Expenses Total Operating Margin		19.6% 24.7%		19.5% 25.7%		20.2% 24.8%		22.4% 16.0%		23.7% 16.7%		21.3% 21.2%		23.3
, , ,														19.3
Tax Rate		30.0%		28.0%		28.0%		28.0%		28.0%		28.0%		28.0
Net Margin		18.3%		19.1%		18.2%		11.9%		12.4%		15.7%		14.4
Growth Statistics: Sequential:														
License Revenue				1.8%		7.7%		-18.3%		-7.0%				
Service Revenue				<u>1.7</u> %		<u>7.7</u> %		- <u>16.3</u> %		- <u>8.0</u> %				
Total Revenues				1.7%		7.7%		-16.5%		-7.9%				
Total Cost of Revenue				0.8%		8.2%		-6.5%		-11.0%				
R&D				-1.8%		8.2%		3.6%		-3.1%				
SG&A				4.9%		13.5%		-13.1%		-1.9%				
Total Operating Expenses				2.5%		11.6%		-7.5%		-2.4%				
rotal operating Expenses				0.00/		2 70/		-46.1%		2.00/				
Total Operating Margin				3.2%		3.7%		-4 0.1/0		-3.8%				
, , ,				3.2% 3.1%		2.7%		-45.5%		-3.6% -3.6%				

Amdocs Ltd. Page 2 of 3



Rating Definitions

Investment Opinion: investment opinions are based on each stock's return potential relative to the overall market*, not an absolute return.

- Strong Buy: Expected to significantly outperform the relevant broader market index over the next 6 to 12 months. An identifiable catalyst is present to drive appreciation.
- Outperform: Expected to outperform the relevant broader market index over the next 12 to 18 months.
- Market Perform: Expected to perform in line with the relevant broader market index over the next 6 to 12 months.
- Underperform: Expected to underperform the relevant broader market index over the next 6 to 12 months.
- * Broader market indices = Russell 2000 and S&P 500

Volatility Rating: Our focus on growth companies implies that the stocks we recommend are typically more volatile than the overall stock market. We are not recommending the "suitability" of a particular stock for an individual investor. Rather, we are identifying the volatility of a particular stock.

- Low: The stock price has moved up or down by more than 10% in a month in fewer than 8 of the past 24 months.
- Medium: The stock price has moved up or down by more than 20% in a month in fewer than 8 of the past 24 months.
- High: The stock price has moved up or down by more than 20% in a month in at least 8 of the past 24 months. All IPO stocks automatically get this risk rating for the first 12 months of trading.

The following disclosures apply to stocks mentioned in this report if and as indicated: (#) U.S. Bancorp Piper Jaffray (USBPJ) makes a market in the company's securities. (^) USBPJ analysts who follow this company, or members of their household, have a beneficial interest in the company's securities. USBPJ analysts or members of their household may sell such positions while a Strong Buy, Outperform, or Market Perform rating is maintained; however, they may do so only upon appropriate USBPJ management approval. (>) USBPJ analysts who follow this company, or members of their household, have a beneficial interest in the company's securities that were acquired in a private transaction pre-IPO. USBPJ analysts or members of their household may sell such positions while a Strong Buy, Outperform, or Market Perform rating is maintained; however, they may do so only upon appropriate USBPJ management approval. (@) Within the past three years, USBPJ was managing underwriter of an offering of, or dealer manager of a tender offer for, the company's securities or the securities of an affiliate. (~) A USBPJ officer, director, or other employee is a director and/or officer of the company.

Nondeposit investment products are not insured by the FDIC, are not deposits or other obligations of or guaranteed by U.S. Bank National Association or its affiliates, and involve investment risks, including possible loss of the principal amount invested.

This material is based on data obtained from sources we deem to be reliable; it is not guaranteed as to accuracy and does not purport to be complete. This information is not intended to be used as the primary basis of investment decisions. Because of individual client requirements, it should not be construed as advice designed to meet the particular investment needs of any investor. It is not a representation by us or an offer or the solicitation of an offer to sell or buy any security. Further, a security described in this release may not be eligible for solicitation in the states in which the client resides. U.S. Bancorp and its affiliated companies, and their respective officers or employees, or members of their families, may have a beneficial interest in the company's securities and may purchase or sell such positions in the open market or otherwise. This report is a communication made in the United Kingdom by U.S. Bancorp Piper Jaffray to market counterparties or intermediate customers and is exclusively directed at such persons; it is not directed at private customers and any investment or services to which the communication may relate will not be available to private customers. In the United Kingdom, no persons other than a market counterparty or an intermediate customer should read or rely on any of the information in this communication. Securities products and services offered through U.S. Bancorp Piper Jaffray, member SIPC and NYSE, Inc., a subsidiary of U.S. Bancorp.

© 2002 U.S. Bancorp Piper Jaffray, 800 Nicollet Mall, Suite 800, Minneapolis, Minnesota 55402-7020

Additional information is available upon request.

Amdocs Ltd. Page 3 of 3